Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01010945 · ClinicalTrials.gov registry record · Phase 1
Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
A Phase 1 study of Advanced Pancreatic Cancer, sponsored by OSI Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 5
- Study locations
NCT01010945 is a Phase 1 study of Advanced Pancreatic Cancer that has completed, run by OSI Pharmaceuticals. The registered enrollment target is 19 participants, below the 74-participant average among 7 other Advanced Pancreatic Cancer trials with a reported enrollment target (74% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT01010945, a Phase 1 study of Advanced Pancreatic Cancer, has completed, sponsored by OSI Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a phase 1b study to evaluate the combination of gemcitabine and Tarceva (erlotinib) and nab-paclitaxel in patients with advanced pancreatic cancer.
Conditions Studied
Interventions
- DRUG nab-paclitaxel
- DRUG gemcitabine
- DRUG erlotinib
Study Locations (5)
California
- Desert Comprehensive Cancer Center - Palm Springs
Colorado
- University of Colorado Cancer Center - Aurora
North Carolina
- University of North Carolina - Chapel Hill
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Tennessee
- Vanderbilt Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2010-02-03 |
| Est. Completion | 2012-01-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01010945
The ClinicalTrials.gov registry entry for NCT01010945 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 74-participant average among 7 other Advanced Pancreatic Cancer trials with a reported enrollment target (74% lower). The listed sponsor is OSI Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which nab-paclitaxel is the first listed.
NCT01010945 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Colorado, North Carolina.
Frequently Asked Questions
What is clinical trial NCT01010945 about?
NCT01010945 is a clinical study titled "Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer". This is a phase 1b study to evaluate the combination of gemcitabine and Tarceva (erlotinib) and nab-paclitaxel in patients with advanced pancreatic cancer.
What is the current status of trial NCT01010945?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2010-02-03. Estimated completion is 2012-01-25.
What conditions does trial NCT01010945 study?
This clinical trial studies the following conditions: Advanced Pancreatic Cancer.
What interventions are being tested in trial NCT01010945?
The interventions under investigation include: nab-paclitaxel (DRUG), gemcitabine (DRUG), erlotinib (DRUG).
Who is sponsoring clinical trial NCT01010945?
This trial is sponsored by OSI Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01010945 being conducted?
This trial has 5 study locations across California, Colorado, North Carolina, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
COMPLETED · Phase 1
-
1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.